Effect of Push-Dose Adrenaline on Peri-intubation Hypotension During Rapid Sequence Intubation in the Emergency Department

Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorMarmara University Pendik Training and Research Hospital

About this trial

Rapid sequence intubation is commonly performed in the emergency department to secure the airway of critically ill patients. However, blood pressure may decrease during or shortly after intubation because of the patient's underlying illness, the effects of induction medications, and the transition to positive-pressure ventilation. This complication is known as peri-intubation hypotension and is associated with worse clinical outcomes.

This study will evaluate whether a preemptive low dose of intravenous adrenaline, also known as epinephrine, can reduce peri-intubation hypotension in adult emergency department patients undergoing rapid sequence intubation. Participants will be randomly assigned to receive either 10 mcg of intravenous adrenaline or 1 mL of 0.9% sodium chloride placebo immediately before induction. The study will compare hemodynamic changes, vasopressor requirements, safety outcomes, and mortality between the two groups.

Eligibility criteria

Qualifiers

Adult patients aged 18 years or older

Patients in the emergency department for whom the treating physician has made a clinical decision to perform rapid sequence intubation

Patients who are hypotensive, defined as systolic blood pressure less than 90 mmHg or mean arterial pressure less than 65 mmHg, or who are considered to be at significant risk of hypotension during rapid sequence intubation

Written informed consent obtained from the patient or from a legally authorized representative when the patient lacks decision-making capacity

Disqualifiers

Pregnancy

Known allergy to adrenaline

Known contraindication to adrenaline administration

Withdrawal of consent by the patient or legally authorized representative after enrollment

Trial design

Treatments tested in this trial

  • Adrenaline
  • 0.9 % sodium chloride

Treatment groups

128 Participants
are divided into 2 treatment groups

Sponsors and collaborators